Summary
Claire Mazumdar, the chief executive officer of Bicara Therapeutics Inc. (NASDAQ: BCAX), completed a sale of common shares valued at $354,145 on April 20, 2026, according to a filing. The transaction occurred as the stock has experienced a notable run-up over the past year, and follows a round of option exercises by Ms. Mazumdar earlier in April.
Details of the sale and option exercises
On April 20, 2026, Ms. Mazumdar sold 15,000 shares of Bicara common stock at a weighted average price of $23.6097 per share. The filing shows individual trade prices ranged from $23.355 to $23.81. The disposition was carried out pursuant to a Rule 10b5-1 trading plan that Ms. Mazumdar adopted on February 12, 2025.
Separately, Ms. Mazumdar acquired 37,760 shares through the exercise of stock options on April 16 and April 20, 2026. The cost of those option exercises totaled $160,206, with exercise prices per share reported between $3.7898 and $5.4537. The filing notes that the acquisition of 15,000 shares on April 20 was also executed under the same Rule 10b5-1 plan that governed the sale.
Post-transaction holdings and outstanding option positions
Following the April transactions, Ms. Mazumdar holds 362,152 shares of Bicara Therapeutics common stock directly. The disclosure also lists remaining option positions available to her: 56,684 options at an exercise price of $4.4369; 130,546 options at $3.7898; 558,432 options at $5.4537; and 161,107 options at $3.7898.
Market context and analyst reactions
The insider activity comes as Bicara's shares have climbed 93% over the last 12 months. InvestingPro analysis cited in the filing suggests the shares may be overvalued at their current levels. The stock is trading near a reported 52-week high of $24.25 and is up 44% over the past six months.
In corporate updates, Bicara Therapeutics reported fourth-quarter 2025 results that highlighted a strong cash position and described promising clinical data for its lead candidate, ficerafusp alfa. The company also disclosed higher operating expenses for the quarter. These corporate developments have influenced investor attention and analyst coverage.
H.C. Wainwright responded to the company’s results by raising its price target for Bicara Therapeutics from $40 to $42 while maintaining a Buy rating. The firm identified several potential catalysts for the company in 2026, including the presentation of long-term follow-up data from a Phase 1b study at ASCO 2026. Citizens reiterated a Market Outperform rating with a $31.00 price target, citing discounted earnings per share and revenue multiple analysis.
Additionally, Bicara supplied updates on ongoing trials of ficerafusp alfa in head and neck squamous cell carcinoma and metastatic colorectal cancer, developments the company described as part of its advancing clinical program.
Takeaway
The April trading by Bicara’s CEO combined a scheduled sale under a Rule 10b5-1 plan with option exercises that materially increased her direct share count, while the company’s recent financial and clinical disclosures have drawn analyst attention and pushed the stock toward its 52-week high. InvestingPro’s valuation caution is noted alongside analyst upgrades and reiterated ratings tied to forthcoming clinical readouts and financial metrics.